Effect of Eliquis (Apixaban) and Clopidogrel on aPTT
Apixaban causes minimal, clinically insignificant prolongation of aPTT that is not useful for monitoring, while clopidogrel has no direct effect on aPTT.
Apixaban's Effect on aPTT
Apixaban does prolong aPTT, but the effect is small, highly variable, and not clinically useful for monitoring anticoagulation 1. The FDA label explicitly states that "changes observed in these clotting tests at the expected therapeutic dose, however, are small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of apixaban" 1.
Key Evidence on Apixaban and aPTT:
Minimal prolongation: At therapeutic doses, apixaban causes only modest aPTT prolongation. Even at supratherapeutic concentrations (225 ng/mL), aPTT was prolonged only 1.15-fold compared to baseline 2
Dose-dependent but limited: In single-dose studies, a 50 mg dose (far exceeding therapeutic levels) increased aPTT by only 1.2-fold from baseline 3
Not reagent-sensitive: Unlike PT testing where reagent choice matters significantly, aPTT reagents show no appreciable difference in sensitivity to apixaban 2
European guidelines confirm: The 2018 EHRA guidelines note that apixaban has limited impact on aPTT compared to other anticoagulants, with the symbol "(↑)" indicating minimal effect 4
Clinical Implications:
Do not use aPTT to monitor apixaban therapy. If you need to assess apixaban levels:
- Use calibrated anti-Factor Xa chromogenic assays for quantitative measurement 4
- A normal aPTT does NOT exclude therapeutic apixaban levels 4
- aPTT cannot reliably guide clinical decisions about apixaban dosing or reversal
Clopidogrel's Effect on aPTT
Clopidogrel does not affect aPTT. Clopidogrel is an antiplatelet agent that inhibits the P2Y12 receptor on platelets—it has no direct effect on the coagulation cascade measured by aPTT. The FDA label for apixaban confirms "no pharmacodynamic interactions were observed with aspirin, clopidogrel, or prasugrel" 1.
Combined Use Considerations
When apixaban and clopidogrel are used together:
- Bleeding risk increases due to combined antiplatelet and anticoagulant effects 1
- aPTT remains unreliable for monitoring either drug
- The combination showed enhanced antithrombotic effects in microfluidic studies but with dose-dependent bleeding risk 5
Important Caveat:
If you're checking aPTT in a patient on both drugs and considering heparin bridging, be aware that apixaban will interfere with aPTT-based heparin monitoring. In this scenario, use anti-Xa activity to monitor heparin instead 6.